GlaxoSmithKline and Roche announce co-development and co-promotion agreement
Given the promising clinical trial results, Roche will be able to take full advantage of the potential of this exciting and promising medicine by collaborating with a strong development and marketing partner. Combining Roche and GSK's development, marketing and sales capabilities will provide the maximum added value for patients and prescribers.
Terms of Agreement
Under the terms of the agreement, Roche and GSK will share the future development and registration costs for the product and Roche will receive certain milestone payments from GSK. Roche will account for all sales of the product. Both companies will share profits. The companies plan to file the first drug applications with the US Food and Drug Administration and in Europe in 2002. Subject to local legal requirements, Roche and GSK plan to co-promote ibandronate in all countries, except Japan.
Topics
Organizations
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.